Document Detail

Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  9817708     Owner:  NLM     Status:  MEDLINE    
Changes in lung hyperinflation, dyspnea, and exercise endurance are important outcomes in assessing therapeutic responses in chronic obstructive pulmonary disease (COPD). Therefore, we studied the reproducibility of Borg dyspnea ratings, inspiratory capacity (IC; to monitor lung hyperinflation), and endurance time during constant-load symptom-limited cycle exercise in 29 patients with COPD (FEV1 = 40 +/- 2% predicted; mean +/- SEM). Responsiveness was also studied by determining the acute effects of nebulized 500 micrograms ipratropium bromide (IB) or saline placebo (P) on these measurements. During each of four visits conducted over an 8-wk period, spirometry and exercise testing were performed before and 1 h after receiving IB or P (randomized, double-blinded). Highly reproducible measurements included: endurance time (intraclass correlation R = 0.77, p < 0.0001); Borg ratings and IC at rest, at a standardized exercise time (STD), and at peak exercise (R > 0.6, p < 0.0001); and slopes of Borg ratings over time, oxygen consumption (V O2), and ventilation (R > 0.6, p < 0.0001). Responsiveness was confirmed by finding a significant drug effect for: change (Delta) in endurance time (p = 0.0001); DeltaBorgSTD and DeltaBorg-time slopes (p < 0.05); and DeltaIC at rest, at STD, and at peak exercise (p = 0.0001). With all completed visits, DeltaBorgSTD correlated better with DeltaICSTD than any other resting or exercise parameter (n = 115, r = -0.35, p < 0.001). We concluded that Borg dyspnea ratings, and measurements of IC and endurance time during submaximal cycle exercise testing are highly reproducible and responsive to change in severe COPD.
D E O'Donnell; M Lam; K A Webb
Related Documents :
11759548 - Breathing pattern retraining and exercise in persons with chronic obstructive pulmonary...
17890458 - Distractive auditory stimuli reduce the unpleasantness of dyspnea during exercise in pa...
20849478 - Characteristics of exercise-induced intrapulmonary arteriovenous fistula in patients wi...
20801268 - Effect of pulmonary rehabilitation on balance in persons with chronic obstructive pulmo...
24531438 - Effects of a single bout of lower body aerobic exercise on muscle activation and perfor...
17519128 - The nts and integration of cardiovascular control during exercise in normotensive and h...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  158     ISSN:  1073-449X     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  1998 Nov 
Date Detail:
Created Date:  1998-12-18     Completed Date:  1998-12-18     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1557-65     Citation Subset:  AIM; IM    
Respiratory Investigation Unit, Departments of Medicine, and Community Health and Epidemiology, Queen's University, Kingston, Ontario, Canada. <>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bronchodilator Agents / administration & dosage,  therapeutic use
Cross-Over Studies
Double-Blind Method
Dyspnea / drug therapy,  physiopathology*
Exercise Test
Follow-Up Studies
Forced Expiratory Volume / drug effects,  physiology
Inspiratory Capacity / drug effects,  physiology*
Ipratropium / administration & dosage,  therapeutic use
Lung / drug effects,  physiopathology*
Lung Diseases, Obstructive / drug therapy,  physiopathology*
Middle Aged
Nebulizers and Vaporizers
Oxygen Consumption / drug effects,  physiology
Physical Endurance / physiology*
Physical Exertion / physiology*
Reproducibility of Results
Respiration / drug effects
Treatment Outcome
Reg. No./Substance:
0/Bronchodilator Agents; 0/Placebos; 60205-81-4/Ipratropium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Positive end-expiratory pressure improves gas exchange and pulmonary mechanics during partial liquid...
Next Document:  Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis.